Objective Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually and it places the highest economic burden of all cancers on the EU at €18.8billion. These figures call for a major transformation of the therapeutic management of lung cancer. The recent developments in immunotherapy give new hope. At present a significant minority of patients benefit from immune therapy, which remains not curative when delivered alone. It is thus clear that improving the efficacy of immune therapy is needed as well as the identification of predictive biomarkers. Combining immunotherapy with radiotherapy improves effectiveness, but resistance is still common, most probably because of hypoxia. In HYPOXIMMUNO, we will open up a new paradigm in treating metastatic NSCLC. I will provide for the first time (pre)clinical proof of concept of (i) highly innovative CT-based radiomics and PET-hypoxia imaging patient stratification tools and (ii) a tri-modal curative hypoxia-targeting treatment strategy that complements current immunotherapy and radiotherapy approaches. This tri-modal curative treatment strategy is based on (1) high precision Stereotactic Radiotherapy (SABR) to kill cancer cells and trigger the immune system, combined with (2) a hypoxia-activated prodrug to target the hypoxic tumour cells resistant to immunotherapy and (3) a promising and innovative tumour specific antibody (Ab)-based immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with or without a checkpoint inhibitor to “release the break”) to form a powerful synergistic immuno-oncology strategy. In HYPOXIMMUNO, I envision to lay the foundation for the next breakthrough in oncology, by improving patient selection and developing highly innovative cancer therapies that target hypoxia, to improve the quality of life and prolong survival of cancer patients, in particular patients with metastatic NSCLC (watch the animation summarising the project: https://youtu.be/oP9Gp4a0b_Q). Fields of science medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesclinical medicineoncologylung cancermedical and health sciencesclinical medicineoncologyskin cancersquamous cell carcinomamedical and health sciencesclinical medicinehematologymedical and health sciencesbasic medicineimmunologyimmunotherapy Keywords Hypoxia radiation immunotherapy lung cancer metastatic disease Stereotactic Ablative Radiotherapy hypoxia-activated-prodrug biomarker patient stratification radiomics immunocytokines Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-ADG-2015 - ERC Advanced Grant Call for proposal ERC-2015-AdG See other projects for this call Funding Scheme ERC-ADG - Advanced Grant Host institution UNIVERSITEIT MAASTRICHT Net EU contribution € 2 402 499,00 Address MINDERBROEDERSBERG 4 6200 MD Maastricht Netherlands See on map Region Zuid-Nederland Limburg (NL) Zuid-Limburg Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 402 499,00 Beneficiaries (2) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITEIT MAASTRICHT Netherlands Net EU contribution € 2 402 499,00 Address MINDERBROEDERSBERG 4 6200 MD Maastricht See on map Region Zuid-Nederland Limburg (NL) Zuid-Limburg Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 402 499,00 ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER France Net EU contribution € 96 900,00 Address 240 AV DU PROF EMILE JEANBRAU 34296 Montpellier Cedex 5 See on map Region Occitanie Languedoc-Roussillon Hérault Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 96 900,00